WeChat· 细胞与基因治疗领域·· 8 hours agoPickScore60
Estuary Biotherapeutics Closes Over 600 Million Yuan Series A to Advance Kidney Disease Gene Therapy Pipeline
In brief
Estuary Biotherapeutics has completed a $93 million Series A financing, equivalent to over 600 million yuan. RA Capital Management led the round, with participation from Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, and the National Kidney Foundation Innovation Fund.
Why it matters
to advance its gene therapy pipeline for kidney disease
Source: WeChat · mp.weixin.qq.com